An official website of the United States government
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Trial Status: active
This phase 3 clinical trial compares the efficacy and safety of palazestrant with
ribociclib to letrozole and ribociclib in women and men who have not received prior
systemic anti-cancer treatment for advanced breast cancer.
Inclusion Criteria
Adult female or male participants.
ER+, HER2- locally advanced or metastatic breast cancer that is not amenable to curative therapy.
Evaluable disease (measurable disease per RECIST 1.1 or bone-only disease).
De novo advanced breast cancer or with disease recurrence occurring after 12 months of completing adjuvant endocrine therapy (with or without CDK4/6 inhibitors)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate hematologic, hepatic, and renal functions.
Female participants can be pre-, peri- or postmenopausal.
Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.
Exclusion Criteria
Disease recurrence during adjuvant endocrine therapy
Currently receiving or previously received systemic anti-cancer therapy for ER+, HER2- advanced breast cancer.
Previously received treatment with fulvestrant, elacestrant or an investigational endocrine therapy in any setting.
History of allergic reactions to study treatment.
Any contraindications to letrozole and ribociclib.
Symptomatic central nervous system metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require immediate treatment.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07085767.
